Medivis, a Brooklyn, New York-based medical imaging and visualization company, as per recent reports last week, has received the 510(k) clearance for its surgical augmented reality platform – SurgicalAR – for clinical use in the operating room from the US Food and Drug Administration (FDA).
Today, most of the surgeons perform medical procedures relatively blindly, by reconstructing the bits and pieces of the 2D imaging data in their “mind’s eye” to make it actionable. The enterprise SurgicalAR platform, which was founded by neurosurgeon Osamah Choudhry (MD) and radiologist Christopher Morley (MD), integrates the latest advancements in augmented reality (AR), artificial intelligence (AI), and computer vision to advance surgical visualization. The platform enables operators with a superior understanding, confidence, efficiency, and precision for every patient.
“Holographic visualization is the final frontier of surgical imaging and navigation,” states Dr. Osamah Choudhry, Neurosurgeon & CEO of Medivis. “The surgical world continues to primarily rely on two-dimensional imaging technology to understand and operate on incredibly complex patient pathology. “
Medivis’ FDA 510(k) clearance announcement follows the company’s strategic partnerships with Verizon and Microsoft. Also, earlier this year, in Feb. 2019, the company announced closing a $2.3 million seed funding round, led by Initialized Capital, a San Francisco, California-based venture capital fund. The company also recently, in Mar. 2019, unveiled its next-gen AnatomyX AR platform for medical training.